Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 8/20 | 0.39 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | CASR | P41180 | 1/20 | 0.34 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.34 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13876051 | 0.81 | RXRA (0.40) | EPHX2 | |
| SCHEMBL13875927 | 0.81 | EPHX2 (0.44) | GCKNR1H3EPHX2 | |
| SCHEMBL13875996 | 0.80 | PIN1 (0.41) | ADRA2AADRA2B | |
| SCHEMBL7983100 | 0.80 | NR1H3 (0.39) | GCKNR1H3ADRA2AADRA2BADRA2C | |
| SCHEMBL13876011 | 0.80 | KDM4E (0.42) | P2RX4LMNA | |
| SCHEMBL13875998 | 0.80 | LOXL2 (0.40) | GCKGPR119 | |
| SCHEMBL13876002 | 0.79 | NR1H2 (0.43) | GCKNR1H3GPR119 | |
| SCHEMBL13875986 | 0.75 | LOXL2 (0.42) | EPHX2 | |
| SCHEMBL13875972 | 0.74 | KCNK3 (0.48) | LMNA | |
| SCHEMBL13876008 | 0.74 | LOXL2 (0.41) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, NCEH1 | GCK 4080/4885P2RX4 1778/4885NR1H3 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.